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Abstract: Background and Aims: Diabetic cardiomyopathy (DCM) is an emerging problem worldwide
due to an increase in the incidence of type 2 diabetes. Animal studies have indicated that metformin
and pioglitazone can prevent DCM partly by normalizing insulin resistance, and partly by other,
pleiotropic mechanisms. One clinical study has evidenced the insulin-senzitizing effect of the drug
candidate BGP-15, along with additional animal studies that have confirmed its beneficial effects
in models of diabetes, muscular dystrophy and heart failure, with the drug affecting chaperones,
contractile proteins and mitochondria. Our aim was to investigate whether the inzulin-senzitizer
BGP-15 exert any additive cardiovascular effects compared to metformin or pioglitazone, using
Goto-Kakizaki (GotoK) rats. Methods: Rats were divided into five groups: (I) healthy control (Wistar),
(II) diseased (GotoK), and GotoK rats treated with: (III) BGP-15, (IV) metformin, and (V) pioglitazone,
respectively, for 12 weeks. Metabolic parameters and insulin levels were determined at the endpoint.
Doppler echocardiography was carried out to estimate diabetes-associated cardiac dysfunction.
Thoracotomy was performed after the vascular status of rats was evaluated using an isolated
aortic ring method. Furthermore, western blot assays were carried out to determine expression
or phosphorylation levels of selected proteins that take part in myocyte relaxation. Results: BGP-15
restored diastolic parameters (e′/a′, E/e′, LAP, E and A wave) and improved Tei-index compared to
untreated GotoK rats. Vascular status was unaffected by BGP-15. Expression of sarco/endoplasmic
reticulum Ca2+-ATPase (SERCA2a) and phosphodiesterase 9A (PDE9A) were unchanged by the
treatments, but the phosphorylation level of vasodilator-stimulated phosphoprotein (VASP) and
phospholamban (PLB) increased in BGP-15-treated rats, in comparison to GotoK. Conclusions: Even
though the BGP-15-treatment did not interfere significantly with glucose homeostasis and vascular
status, it considerably enhanced diastolic function, by affecting the SERCA/phospholamban pathway
in GotoK rats. Although it requires further investigation, BGP-15 may offer a new therapeutic
approach in DCM.
Keywords: diastolic dysfunction; type 2 diabetes; Goto-Kakizaki; BGP-15; metformin; pioglitazone;
echocardiography; endothelial dysfunction
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1. Introduction
With the increasing incidence of diabetes mellitus (DM), the cardiovascular (CV) complications of
DM are an emerging problem worldwide that needs to be addressed. The development of heart
failure (HF) in type 2 diabetes mellitus (T2DM) patients is considered to be independent from
other risk factors, such as hypertension, coronary artery disease (CAD) or myocardial infarction [1].
Although proper glucose management reduces CV risk in DM patients, CV event rate is still more
frequent than in healthy population, with a 2-5-fold increase in HF risk [2,3]. Diabetic cardiomyopathy
(DCM) is diagnosed as characterized by LV diastolic dysfunction and hypertrophy, with or without
systolic abnormalities [4]. There are several mechanisms that contribute to the pathophysiology
of DCM, including metabolic alterations, inflammation and oxidative stress [1], which will all
cause membrane disturbances, calcium-handling abnormalities and sarco/endoplasmic reticulum
Ca2+-ATPase (SERCA2a) pump dysfunction [1,5]. These processes may lead to relaxation abnormalities,
myocyte apoptosis and CV dysfunction [6].
The Goto-Kakizaki (GotoK) strain is one of the most widely used rat model of type 2 diabetes in
preclinical research [7]. GotoK rats exhibit mild hyperglycemia, and impaired glucose tolerance, while
being normotensive and non-obese at the same time. Thus, they constitute a valuable means for the
specific characterization of CV complications caused by hyperglycemia and diabetes only, without the
presence of other risk factors [8]. Moreover, GotoK rats display left ventricle (LV) structural remodeling
as early as the prediabetes stage, while later on they develop significant cardiomyopathy and diastolic
dysfunction [8,9].
Of all the antidiabetic drugs, metformin is currently recommended by the main clinical practice
guidelines collectively to use in the vast majority of T2DM patients. Based on a systemic review
of observational studies, metformin decreases the mortality in diabetic patients with congestive
heart failure [10], and possesses beneficial pleiotropic effects on vascular status [11,12]. Another
particularly interesting agent in the field of DCM therapy is pioglitazone, an insulin-sensitizer from
the thiazolidinedione (TZD) class of nuclear peroxisome proliferator-activated receptor γ-agonists,
which decreases insulin resistance in the liver and peripheral tissues. Moreover, it also exhibits
anti-arteriosclerotic and anti-inflammatory effects [13,14]. Even though members of the TZD family
initially were seemingly promising antidiabetic drugs with pleiotropic properties, The European
Society of Cardiology (ESC) stated in a recent guideline that this group is not recommended for any
patient with heart failure, due to its potential of causing fluid retention [10].
In the last decade, the hydroxylamine derivative BGP-15 (O-(3-piperidino-2-hydroxy-1-propyl)
nicotinic amidoxime) has increasingly raised scientific interest. The rationale for assessing the
potential of BGP-15 here, in a model of early-stage diabetic cardiomyopathy, was related to earlier
reports of the molecule, as BGP-15 exhibited insulin-sensitizing properties, protective effects against
muscular dystrophy, cardiotoxicity, heart failure and atrial fibrillation [15–17]. BGP-15 increased tissue
insulin-sensitivity in different animal models of metabolic disorders at 10–30 mg/kg doses [18]. BGP-15
entered clinical phase I–II as an insulin-sensitizer, and proved to increase tissue insulin-sensitivity in
200 mg/day and 400 mg/day doses in human patients. It was proven to be particularly safe, causing
no clinical side effects or ECG-disturbances [16–18]. Parallel animal experiments have shown that
BGP-15 increases the expression of heat shock proteins (hsp-s) in certain cells, thus accelerates the
regeneration of m. soleus myocytes after cryolysis in 15 mg/kg dose in CB6F1 mice. BGP-15 increased
the rate of regeneration, and also improved the contractile function after damage, by accelerating
the re-expression of adult myosin heavy chain (MyHC-II and MyHC-I) isoforms and induction of
chaperones [17]. Furthermore, 10 days of BGP-15 treatment greatly improved diaphragm muscle
fiber function when administered at a dose of 40 mg/kg per day to Sprague-Dawley rats suffering
ventilation-induced diaphragm-dysfunction. The treatment provided a protective effect from myosin
post-translational modifications, associated with hsp72-induction and polyADP-ribose polymerase 1
(PARP-1) inhibition, resulting in an improvement of mitochondrial function [19]. In another experiment
Sapra et al. showed that BGP-15-treatment did not alter the levels of hsp70 or hsp27 in the myocardial
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tissue, although it increases the phosphorylation of the insulin-like growth factor-1 receptor (IGF1R) in
15 mg/kg dose and also enhanced the expression of SERCA2a gene, moreover inhibited atrial and
B-type natriuretic peptide (ANP and BNP) expression. In these experiments, the heart and lungs of
the rats were enlarged with collagen deposits, which was counteracted by BGP-15-treatment, as a
possible result of a cardioprotective mechanism resulting from IGF1R phosphorylation [16]. It was
also reported that BGP-15 (15 mg/kg per day, oral gavage) improved muscle strength and endurance
of dystrophic mdx transgenic mice, reduced fibrosis of diaphragm muscle, and increased maximal
SERCA activity in diaphragm homogenates [15].
Based on the aforementioned facts, it is likely that BGP-15 has anti-diabetic properties on one
hand, and it may enhance muscle function through various mechanisms. In light of the foregoing,
this current study was aimed at investigating the effects of BGP-15 in the Goto-Kakizaki non-obese
model of T2DM, comparing the drug candidate to the therapeutic golden-standard metformin, and
to the insulin-sensitizer pioglitazone with particular interest on cardiac and vascular parameters,
and signaling.
2. Results
2.1. Metabolic Characterisation of Goto-Kakizaki and Wistar Rats
Table 1 and Figure 1 show serum glucose and insulin levels, as well as the body weight of rat
groups (Wistar, GotoK, and GotoK rats treated with BGP-15, metformin and pioglitazone, respectively
for 12 weeks). The initial body weights were not significantly different among the four GotoK groups.
Despite the random sorting, GotoK and GotoK + MET group showed slightly lower baseline body
weights compared to the Wistar group. GotoK groups were roughly resistant to weight gain, with
one exception: at the endpoint, Dunn’s post hoc test revealed differences between the MET and PIO
group in weight gain. After the 12-week period, fasting glucose level of GotoK rats was significantly
higher than those of the Wistar controls, and although all treatments reduced serum glucose, only the
pioglitazone treatment was able to exert significant effectiveness (p < 0.05). Insulin sensitivity markers
were calculated from basal endpoint serum glucose and insulin levels, of which homeostasis model
assessment-estimated insulin resistance (HOMA-IR) showed significant differences in GotoK group
compared to Wistar (p < 0.05).
Table 1. Fasting serum glucose, fasting plasma insulin levels, and body weights before (baseline) and
after (endpoint) the treatment.
Parameter Fasting Glucose(mmol/L)
Fasting Insulin
(µIU/mL)
Baseline
BODYWEIGHT (g)
Endpoint
Bodyweight (g)
Wistar 6.280 ± 0.428 5.850 ± 0.132 407.8 ± 3.798 539.8 ± 22.45
GotoK 13.62 ± 0.626 * 12.53 ± 3.292 313.8 ± 4.070 * 374.0 ± 6.266 *
GotoK+BGP15 10.92 ± 0.561 12.30 ± 3.793 318.3 ± 5.566 383.8 ± 9.024
GotoKMET 11.20 ± 1.002 12.82 ± 4.104 312.7 ± 5.655 * 361.7 ± 12.27 *
GotoK+PIO 7.880 ± 0.312 # 14.83 ± 2.768 316.3 ± 3.658 411.3 ± 10.40
Metabolic parameters were determined in control (Wistar) and diabetic (GotoK) rats treated with placebo (GotoK),
BGP-15 (GotoK + BGP15), metformin (GotoK + MET) and pioglitazon (GotoK + PIO). Values are presented as mean
±SEM, n = 6/group, Kruskal-Wallis test with Dunn’s post-test. * vs. Wistar; # vs. GotoK, (p < 0.05).
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Figure 1. Metabolic parameters in control (Wistar) and diabetic (GotoK) rats treated with vehicle 
(GotoK), BGP-15 (GotoK + BGP15), metformin (GotoK + MET) and pioglitazone (GotoK + PIO). (a) 
calculated body weight gain in per cent; (b) calculated fasting glucose/insulin ratio; (c) calculated 
homeostasis model assessment-estimated insulin resistance (HOMA-IR) index; (d) calculated 
HOMA-B index. Values are presented as mean ±SEM; asterisks (*) denotes significance (Kruskal-
Wallis test with Dunn’s post-test, n = 6/group, * p < 0.05; ** p < 0.01). 
2.2. Endothelium-Dependent Vasorelaxation is Enhanced by Pioglitazone but not BGP-15 
In aortic samples of Wistar rats, 10 µmol/L Ach reduced the aortic tension to approximately 50% 
of the pre-contraction elicited by 10 nmol/L norepinephrine. In the group of GotoK rats without 
antidiabetic treatment, response to Ach showed a decrease in comparison with that of the Wistar rats 
(the lack of statistical significance is probably due to the relatively small sample size and the 
consequent big scatter), thus, the GotoK rats showed impaired endothelial function as compared to 
the Wistar rats. 
Treatment with BGP-15 and metformin did not significantly improve the deteriorated 
susceptibility of Goto-Kakizaki rat aorta to Ach, although metformin appeared to enhance the 
endothelium-dependent arterial relaxation at higher doses. In contrast, pioglitazone considerably 
increased the response to Ach, that was statistically significant at 100 nmol/L and 1 µmol/L Ach 
concentrations (when compared to the GotoK group). Moreover, GotoK rats treated with 
pioglitazone exhibited a greater (p = 0.1261 at 0.1 µmol/L Ach) endothelium-dependent arterial 
relaxation than Wistars (Figure 2). 
  
Figure 1. Metabolic parameters in control (Wistar) and diabetic (GotoK) rats treated with vehicle
(GotoK), BGP-15 (GotoK + BGP15), metformin (GotoK + MET) and pioglitazone (GotoK + PIO).
(a) calculated body weight gain in per cent; (b) calculated fasting glucose/insulin ratio; (c) calculated
homeostasis model assessment-estimated insulin resistance (HOMA-IR) index; (d) calculated HOMA-B
index. Values are presented as mean ±SEM; asterisks (*) denotes significance (Kruskal-Wallis test with
Dunn’s post-test, n = 6/group, * p < 0.05; ** p < 0.01).
2.2. Endothelium-Dependent Vasorelaxation is Enhanced by Pioglitazone but not BGP-15
In aortic samples of Wistar rats, 10 µmol/L Ach reduced the aortic tension to approximately
50% of the pre-contraction elicited by 10 nmol/ norepinephrine. In the group of GotoK rats without
antidiabetic treatment, response to Ach showed a decrease in comparison with that of the Wistar
rats (the lack of statistical significance is probably due to the relatively small sample size and the
consequent big scatter), thus, the GotoK rats showed impaired endothelial function as compared to the
Wistar rats.
Treatment with BGP-15 and metformin did not significantly improve the deteriorated
susceptibility of Goto-Kakizaki rat aorta to Ach, although metformin appeared to enhance the
endothelium-dependent arterial relaxation at higher doses. In contrast, pioglitazone considerably
increased the response to Ach, that was statistically significant at 100 nmol/L and 1 µmol/L Ach
concentrations (when compared to the GotoK group). Moreover, GotoK rats treated with pioglitazone
exhibited a greater (p = 0.1261 at 0.1 µmol/L Ach) endothelium-dependent arterial relaxation than
Wistars (Figure 2).
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Figure 2. Relaxant effect of acetylcholine (Ach) on the abdominal aorta isolated from Wistar and Goto-
Kakizaki rats, and GotoK rats treated orally with BGP-15, metformin or pioglitazone. All aortic rings 
underwent a pre-contraction elicited by norepinephrine before the administration of Ach. The axis x 
shows the common logarithm of molar concentration of Ach, while the axis y denotes the effect as a 
percentage decrease of the initial tension of aortic rings. The symbols represent the effect of Ach 
averaged within the groups (±SEM). Asterisks indicate the significance level of differences between 
responses to Ach in GotoK and pioglitazone-treated GotoK rats (* p < 0.05). n = 6/group, one-way 
ANOVA (with Geisser–Greenhouse correction) followed by Tukey post-testing. 
2.3. BGP-15 Enhances Diastolic Function Measured by Echocardiography 
Diastolic function assessed by echocardiography worsened in GotoK rats compared to Wistars, 
but was restored in the GotoK + BGP15 group (Table 2 and Figure 3a–f). The ratio of early and late 
diastolic mitral annular velocities (e′/a′) was reversed in the GotoK group (0.744 ± 0.056, p = 0.0386 vs. 
Wistar), but was elevated significantly in BGP-15-treated rats (1.458 ± 0.155, p = 0.0023 vs. GotoK). 
E/e′ ratio (indicative for LV filling pressure) increased in GotoK rats (p = 0.0045 vs. Wistar), but was 
normalized in GotoK + BGP15 group (p = 0.0019 vs. GotoK). Both early (E) and atrial (A) peak mitral 
filling velocities increased in GotoK (p = 0.002, and p = 0.1806 vs. Wistar), but decreased in BGP-15-
treated group (p = 0.0093, and p = 0.0499 vs. GotoK). E/A ratios and DecT were not significantly 
different in GotoK and Wistar groups. 
Table 2. Echocardiographic parameters of rats, obtained by 2D, M-mode, Doppler (PW) and tissue 
Doppler (TDI) imaging at the endpoint of the study.  
Parameter Wistar GotoK GotoK + BGP-15 GotoK + MET GotoK + PIO 
LVIDd (mm) 7.267 ± 0.278 6.918 ± 0.167 7.243 ± 0.183 6.483 ± 0.425 7.323 ± 0.400 
LVIDs (mm) 4.365 ± 0.201 4.515 ± 0.095 4.69 ± 0.193 3.940 ± 0.200 4.478 ± 0.345 
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MV A vel. (m/s) 0.402 ± 0.048 0.507 ± 0.023 0.372 ± 0.022 # 0.457 ± 0.021 0.480 ± 0.032 
E/A ratio 1.554 ± 0.070 1.735 ± 0.117 1.762 ± 0.066 1.698 ± 0.0840 1.645 ± 0.089 
MV DecT (ms) 53.83 ± 3.692 62.33 ± 2.883 55.00 ± 3.759 58.00 ± 3.425 53.00 ± 3.162 
e′/a′ ratio 1.284 ± 0.158 0.744 ± 0.056 * 1.458 ± 0.155 # 1.249 ± 0.153 0.968 ± 0.032 
E/e′ 16.48 ± 1.512 24.92 ± 1.114 ** 16.31 ± 0.918 ## 20.58 ± 0.766 19.74 ± 1.156 
LAP * (mmHg) 22.34 ± 1.875 32.79 ± 1.381 ** 22.12 ± 1.138 ## 27.42 ± 0.949 26.38 ± 1.433 
LVOT Vmax (m/s) 0.768 ± 0.037 0.998 ± 0.026 ** 0.780 ± 0.029 # 0.768 ± 0.008 # 0.812 ± 0.039 
Figure 2. Relaxant effect of acetylcholine (Ach) on the abdominal aorta isolated from Wistar and
Goto-Kakizaki rats, d GotoK rats treated orally with BGP-15, metformin or pioglitazone. All a rtic
rings underwent a pre-contraction elicited by norepinephrine before the administration of Ach. The
axis x shows the common logarithm of molar concentration of Ach, while the axis y denotes the effect
as a percentage decrease of the initial tension of aortic rings. The symbols represent the effect of Ach
averaged within the groups (±SEM). Asterisks indicate the significance level of differences between
responses to Ach in GotoK and pioglitazone-treated GotoK rats (* p < 0.05). n = 6/group, one-way
ANOVA (with Geisser–Greenhouse correction) followed by Tukey post-testing.
2.3. BGP-15 Enhances Diastolic Function Measured by Echocardiography
Diastolic function assessed by echocardiography worsened in GotoK rats compared to Wistars, but
was restored in the GotoK + BGP15 group (Table 2 and Figure 3a–f). The ratio of early and late diastolic
mitral annular velocities (e′/a′) was reversed in th GotoK group (0.744 ± .056, p = 0.0386 vs. Wi tar),
but was elevated significan ly in BGP-15-treated rats (1.458 ± 0.155, p = 0.0023 vs. GotoK). E/e′ ratio
(indicative for LV filling pressure) increased in GotoK rats (p = 0.0045 vs. Wistar), but w s normalized
in GotoK + BGP15 group (p = 0.0019 vs. GotoK). Both early (E) and atrial (A) peak mitral filling
velocities increased in GotoK (p = 0.002, and p = 0.1806 vs. Wistar), but decreased in BGP-15-treated
group (p = 0.0093, and p = 0.0499 vs. GotoK). E/A ratios and DecT were not significantly different in
GotoK and Wistar groups.
Table 2. Echocardiographic parameters of rats, obtained by 2D, M-mode, Doppler (PW) and tissue
Doppler (TDI) imaging at the endpoint of the study.
Parameter Wistar GotoK GotoK + BGP-15 GotoK + MET GotoK + PIO
LVIDd (mm) 7.267 ± 0.278 6.918 ± 0.167 7.243 ± 0.183 6.483 ± 0.425 7.323 ± 0.400
LVIDs (mm) 4.365 ± 0.201 4.515 ± 0.095 4.69 ± 0.193 3.940 ± 0.200 4.478 ± 0.345
FS (%) 39.94 ± 1.474 33.27 ± 1.667 37.62 ± 0.727 38.85 ± 1.715 39.21 ± 1.608
EF (%) 68.92 ± 1.813 60.36 ± 2.343 66.13 ± 0.891 67.94 ± 2.068 67.98 ± 2.110
MV E vel. (m/s) 0.612 ± 0.047 0.883 ± 0.024 ** 0.648 ± 0.021 ## 0.763 ± 0. 25 0.810 ± 0. 3
MV A vel. (m/s) 0.402 ± 0.048 0.507 ± 0. 23 0.372 ± 0.022 # 0.457 ± 0.021 0.480 ± 0. 32
E/A ratio 1.554 ± 0.070 1.735 ± 0.117 1.762 ± 0.066 1.69 ± 0.08 0 1.645 ± 0.089
MV DecT (ms) 53.83 ± 3.692 62.33 ± 2.883 55.00 ± 3.759 58.00 ± 3.425 53.00 ± 3.162
e′/a′ ratio 1.284 ± 0.158 0.744 ± 0.056 * 1.458 ± 0.155 # 1.249 ± 0.153 0.968 ± 0.032
E/e′ 16.48 ± 1.512 24.92 ± 1.114 ** 16.31 ± 0.918 ## 20.58 ± 0.766 19.74 ± 1.156
LAP * (mmHg) 22.34 ± 1.875 32.79 ± 1.381 ** 22.12 ± 1.138 ## 27.42 ± 0.949 26.38 ± 1.433
LVOT Vmax (m/s) 0.768 ± 0.037 0.998 ± 0.026 ** 0.780 ± 0.029 # 0.768 ± 0.008 # 0.812 ± 0.039
IVCT (ms) 15.67 ± 2.906 18.00 ± 3.777 18,83 ± 3.516 22.83 ± 3.167 16.83 ± 2.272
IVRT (ms) 32.50 ± 1.258 30.33 ± 3.007 32.50 ± 1.057 35.17 ± 1.515 34.00 ± 1.438
LV ET (ms) 87.67 ± 3.116 63.67 ± 1.961 * 101.7 ± 3.703 ### 87.83 ± 5.282 80.67 ± 1.745
Tei-index (MPI) 0.558 ± 0.058 0.724 ± 0.051 0.471 ± 0.027 # 0.669 ± 0.055 0.632 ± 0.039
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Table 2. Cont.
Parameter Wistar GotoK GotoK + BGP-15 GotoK + MET GotoK + PIO
RV E vel. (m/s) 0.332 ± 0.026 0.497 ± 0.044 0.368 ± 0.034 0.383 ± 0.048 0.364 ± 0.027
RV A vel. (m/s) 0.498 ± 0.041 0.628 ± 0.073 0.578 ± 0.033 0.235 ± 0.003 # 0.356 ± 0.074
Parameters measured are as the follows: Left ventricle internal diameter in systole and diastole (LVIDd, LVIDs); left
ventricle fractional shortening (FS), ejection fraction (EF); early mitral filling velocity (MV E vel.); late (atrial) filling
velocity (MV A vel.); ratio of mitral early/atrial peak velocities (E/A ratio); deceleration time of E wave (MV DecT);
ratio of early diastolic mitral annular velocity/late (atrial) diastolic annular velocity (e′/a′ ratio); ratio of early mitral
filling velocity/early diastolic mitral annular velocity (E/e′); calculated Left Atrial Pressure (LAP); maximal velocity
of left ventricle outflow tract (LVOT Vmax); isovolumic contraction time (IVCT); isovolumic relaxation time (IVRT),
left ventricle ejection time (LV ET); Tei-index as myocardial performance index (MPI); right ventricle early filling
velocity (RV E vel.); right ventricle late filling velocity (RV A vel.). GotoK rats exhibited differences in E/e′, E wave,
e′/a′, LVOT Vmax, LV ET and RV E wave in comparison to the Wistar controls. The abovementioned parameters
were significantly improved in the BGP-15 treated GotoK rats, compared to the untreated GotoK animals. Data
is expressed as mean ±SEM, n = 6/group, Kruskal-Wallis test with Dunn’s post-test; * vs. Wistar (p < 0.05); ** vs.
Wistar (p < 0.01); # vs. GotoK (p < 0.05); ## vs. GotoK (p < 0.01); ### vs. GotoK (p < 0.001).Molecules 2018, 23, x FOR PEER REVIEW  7 of 18 
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performance, shown as Tei-index of treatment groups. All data is presented as mean SEM, n = 
6/group, Kruskal-Wallis test with Dunn’s post-test. Asterisks denote the level of significance (* p < 
0.05; ** p < 0.01). 
Systolic function was slightly worsened in GotoK group, as left ventricle ejection time (LV ET) 
was shortened (p = 0.05 vs. Wistar), but increased in the GotoK+BGP15 groups (p = 0.0001 vs. GotoK), 
and fractional shortening (FS) showed non-significant decrease (p = 0.087 vs. Wistar). Global 
myocardial performance assessed as Tei-index slightly worsened in the GotoK group (p = 0.388 vs. 
Wistar) and increased significantly in the BGP-15-treated animals (p = 0.0147 vs. GotoK). 
GotoK rats treated with metformin had preserved annular e′ to a′ ratios, systolic function 
(fractional shortening, ejection fraction), however, parameters did not reach the level of significance 
in comparison to GotoK group. Echocardiographic parameters of pioglitazone-treated did not differ 
significantly from untreated GotoK rats. 
Figure 3. Echocardiographic parameters of rat groups. Data and representative images obtained
from healthy control ( istar) and diabetic GotoK rats treated with vehicle (GotoK), 10 mg/kg BGP-15
(GotoK + BGP15), 100 mg/kg metformin (Got K + M ) 10 g/kg pioglitazone (GotoK + PIO).
(a) representative images of eptal annular tissue velocities ′ ′ and a′ waves) of rats, ecorded by
TDI echocardiography; (b) representative images of mitral inflow velocities (E and A waves), obtained
by Doppler imaging, and representative parasternal long axis views of the left ventricle, obtained by
M-mode (EF: ejection fraction); (c) graph of septal e′/a′ ratio of treatment groups; (d) calculated E/e′
ratios of rats; (e) graph of mitral valve (MV) atrial (A)-wave velocities; (f) myocardial performance,
shown as Tei-index of treatment groups. All data is presented as mean SEM, n = 6/group, Kruskal-Wallis
test with Dunn’s post-test. Asterisks denote the level of significance (* p < 0.05; ** p < 0.01).
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Systolic function was slightly worsened in GotoK group, as left ventricle ejection time (LV ET) was
shortened (p = 0.05 vs. Wistar), but increased in the GotoK+BGP15 groups (p = 0.0001 vs. GotoK), and
fractional shortening (FS) showed non-significant decrease (p = 0.087 vs. Wistar). Global myocardial
performance assessed as Tei-index slightly worsened in the GotoK group (p = 0.388 vs. Wistar) and
increased significantly in the BGP-15-treated animals (p = 0.0147 vs. GotoK).
GotoK rats treated with metformin had preserved annular e′ to a′ ratios, systolic function
(fractional shortening, ejection fraction), however, parameters did not reach the level of significance
in comparison to GotoK group. Echocardiographic parameters of pioglitazone-treated did not differ
significantly from untreated GotoK rats.
2.4. BGP-15 Elevates the Phosphorylation Level of Phospholamban and VASP Proteins
Western blot analyses carried out by phospho-specific antibodies (for the serine-16 (Ser16) residue
of phospholamban (PLB), and serine-239 (Ser239) residue of vasodilator-stimulated phosphoprotein
(VASP)), revealed significant differences in phosphorylation levels of PLB and VASP in myocardial
tissues of rat groups (Figure 4a–b).
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obtained by Western blot. (a) phospho(Ser16)-phospholamban (pPLB) to phospholamban (PLB)
ratios in groups of rats; (b) phopsho(Ser239)-vasodilator-stimulated phosphoprotein (pVASP) to
vasodilator-stimulated phosphoprotein (VASP) ratios; (c) sarcoplasmic/endoplasmic reticulum calcium
ATPase 2a (SERCA2a) levels, normalized to GAPDH as a housekeeping protein; (d) expression level of
phosphodiesterase 9A (PDE9A) levels, normalized to GAPDH. All data is presented as mean ±SEM,
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The ratio of phosphor(Ser16)-PLB to unphosphorylated PLB (pPLB to PLB ratio) was significantly
decreased in the GotoK group in comparison to Wistar (p = 0.0171), but increased in the GotoK +
BGP15 groups compared to untreated GotoK (p = 0.0348). Metformin treatment showed similar trend
(p = 0.1432, vs. GotoK).
As the serine-239 residue of PLB is a phosphorylation target of Protein Kinase G (PKG), expression
of phospho(Ser239)-VASP (indicative for PKG activity) was also measured, and phospho(Ser239)-VASP
to unphosphorylated VASP ratios (pVASP to VASP) in each subjects were calculated (Figure 4b).
Ratio of pVASP to VASP showed similar trend as those of pPLB to PLB, as the pVASP to VASP ratio
significantly increased in the GotoK + BGP15 group in comparison to untreated GotoK (p = 0.0094),
and also showed non-significant increase in metformin-treated rats (p = 0.0877 vs. GotoK).
Expression of SERCA2a was found to be unchanged among treatment groups (Figure 4c). The
expression levels of phosphodiesterase 9A (PDE9A; Figure 4d), responsible for the degradation of
cyclic-guanosine monophosphate (cGMP) did not differ significantly among groups.
3. Discussion
Diabetes incidence is increasing worldwide, and the progression of the disease leads to several
life-threatening complications, as diabetes affects most tissues of the human body, causing multi-organ
damage. The cardiovascular system is of particular importance, proven by the fact that two-third
of diabetes-related mortality is caused by CV events [20]. Diabetes-associated cardiac disease may
appear in a form of (1) coronary artery disease (CAD), (2) autonomic neuropathy (CAN), or (3)
diabetic cardiomyopathy (DCM), which is thought to be underdiagnosed in several cases, despite its
unquestionable importance, in particular regarding the fact that diabetes carries a 2-5-fold increase in
heart failure risk, and 30–60% of the T2DM patients have diastolic dysfunction [20,21].
Several mechanisms have been proposed to contribute to the pathological changes in diabetic
cardiomyopathy, including: metabolic abnormalities, autonomic dysfunction, inflammation, oxidative
stress and subcellular signaling disturbances, demonstrating the complexity of the condition [1].
Among molecular mechanisms, three processes: mitochondrial dysfunction, endoplasmic reticulum
(ER) stress and impaired calcium (Ca) handling are particularly important. These abnormalities may
be the consequence of oxidative stress caused by increased reactive oxygen species (ROS) production
and by the formation of advanced glycation end products (AGEs): damaged and reactive proteins,
that are capable of forming cross-links between structural components of the cell, or disturb the
function of other proteins and enzymes. AGEs exert detrimental effects once by their biochemical
properties, and also by acting via specific receptors (RAGEs), through which transcription factors of
proinflammatory genes are activated [1,5]. Increased production of ROS and AGEs cause stress and
damage in the endoplasmic reticulum by disturbing protein folding, post-translational modifications
and Ca-handling. ER stress causes membrane instability, Ca-handling abnormalities and diminishes
the activity of sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA2a) pump, resulting
in lengthened relaxation, impaired diastolic function, myocyte apoptosis and cell death [6]. The
deteriorated function of SERCA2a pump was also confirmed in myocardial samples of type 1 diabetic
(T1DM), streptozotocin-induced diabetic rats, as a result of hyperglycemia [6]. Furthermore, it was
previously shown that nitro-oxidative stress, and apoptosis accompanied by systolic dysfunction are
more prominent in T1DM models, while in T2DM, cardiomyocyte hypertrophy, stiffness and diastolic
dysfunction are more characteristic [22].
In this study, we attempted to compare the effect of two standard antidiabetic drug (metformin,
pioglitazone) with a promising drug candidate, hydroxamic-acid derivative BGP-15. For the sake of
completeness, we examined their impact on metabolic parameters as well, even though this current
study was aimed to assess the cardiovascular profile of the agents. Here, we confirmed that the
GotoK rats had T2DM characterized by mild hyperglycemia and modest hyperinsulinemia without
weight gain [9]. Which concerns of glucose homeostasis, GotoK rats showed the signs of insulin
resistance to the end of 12-week-long treatment. Fasting glucose level was significantly elevated, while
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fasting insulin was slightly increased compared to the values of the control group. To further confirm
the insulin resistance in GotoK model, HOMA-IR were calculated from basal glucose and insulin
levels, as a widely used insulin sensitivity marker [23]. Basal glucose and HOMA-IR were significantly
elevated in GotoK rats, but decreased after pioglitazone-treatment, moreover, improved NO-dependent
endothelial function was measured in the GotoK+PIO group. In accordance with our results, several
recent studies indicate that thiazolidinediones are able to improve endothelial function, yet the exact
mechanisms are yet to be determined [24,25]. In fact, the exact pathophysiological processes by
which insulin resistance contributes to endothelial dysfunction are mysterious as well, despite the fact
that the last two decades of research have established the crucial role of endothelial cells in defense
against metabolic syndrome [26]. On the other hand, in our setting, pioglitazone-treated animals
exhibited marked weight gain, especially in comparison with the metformin-treated group. Besides
this one exception, there were no significant differences in body weight change among treatment
groups. As long as GotoK is a non-obese spontaneous T2DM model, weight gain can be regarded
as an adverse event [27]. It is believed by that the weight gain is the result of water retention, yet
Hallakou et al. described that pioglitazone stimulates adipocyte differentiation in vivo and induces an
increase in glucose utilization in the adipose tissue by increasing the expression of insulin-responsive
GLUT, fatty acid synthase, and phosphoenolpyruvate carboxykinase genes [28,29]. Additionally,
body-weight-increasing action of pioglitazone is a disadvantage in diabetic patients, since obesity
aggravates diabetes and promotes cardiovascular diseases and atherosclerosis [30]. According to our
knowledge, weight gain is the major problem that may limit the therapeutic value of pioglitazone [31].
Moreover, a recent meta-analysis showed that although pioglitazone-treatment is associated with
reduced risk of non-fatal CVD events and insulin-resistance, it may increase the risk of weight gain,
edema and heart failure [32].
Echocardiographic parameters presented here show marked differences between treatment
groups. Untreated GotoK rats exhibited mild diastolic dysfunction demonstrated by reversed tissue
e′/a′ ratios, elevated E/e′ ratios (indicative for LV filling pressure) and mitral A wave, compared to
age-matched Wistar animals. With E/A ratios higher than 1, increased A wave, reversed e′/a′ and
highly elevated E/e′ ratios, untreated GotoK rats showed similar pattern of diastolic dysfunction to
the nominal “pseudonormal” or Grade 2 diastolic dysfunction described in guidelines for human
patients [33]. Metformin treatment did not delay the onset of diastolic dysfunction, although some
parameters (e′/a′, FS) showed trend towards increase, and endothelium-dependent vasorelaxation
was slightly improved, in accordance with findings of other investigators, who previously showed that
metformin reduces oxidative stress, thus improves endothelial function in diabetic rats [11]. Serum
glucose levels of metformin-treated animals only showed a non-significant decrease in comparison to
GotoK rats. The effectiveness of metformin in reducing blood glucose of GotoK rats is controversial
in literature. Sena et al. showed that MET decreases blood glucose even at 60 mg/kg dose in GotoK
rats [11], while Tae et al. showed that metformin failed to reduce baseline serum glucose levels of GotoK
rats, and only improved glucose tolerance in OGT tests, even in much higher (300 mg/kg) doses [34].
As GotoK rats are insulin-resistant to some extent and have reduced beta cell mass [35], additionally,
metformin primarily decreases plasma glucose by activating its utilization in the GotoK rat [36], we
assume that in our setting, the relative ineffectiveness of metformin may be the result of the smaller
dose (100 mg/kg) or the relatively small (n = 6) number of tested animals. Pioglitazone, although
reduced serum glucose and restored endothelium-dependent vasorelaxation, failed to significantly
improve echocardiographic parameters in this experiment, which may partly be associated with
weight gain.
Notwithstanding, echocardiographic examination BGP-15-treated rats revealed that the treatment
restored diastolic parameters, and also improved myocardial performance in GotoK animals, despite
the fact that it failed to improve endothelial function, or significantly reduce blood glucose levels in
our experimental setting. Transmitral Doppler revealed normal E/A ratios, and significantly improved
E and A velocities compared to GotoK rats. Transmitral Doppler alone however is not enough
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to properly assess and classify the grade of diastolic dysfunction, and needs to be complemented
with other decisive approaches, such as Tissue Doppler Imaging (TDI), a more sensitive method in
evaluating chamber relaxation and estimating pressure relationships [37]. Here, we show that tissue
e’/a’ ratio was significantly increased in BGP-15-treated rats, and E/e’ ratios were significantly lower
in comparison to diseased GotoK. Ratio of E/e’ is a reliable indicator of LV filling pressure, additionally,
echocardiographic estimation of filling pressure may provide similar information to invasive cardiac
catheterization, making it an attractive way to diagnose relaxation abnormalities [38]. Accordingly,
determination of E/e’ ratios allows us to estimate the left atrial pressure (LAP). LAP values of BGP-15
treated rats showed similar pattern to E/e′ ratios, and decreased significantly (to the control level)
in comparison to GotoK rats. Besides diastolic parameters, BGP-15 treatment also improved other
variables, as LV ejection time (LV ET) significantly increased in GotoK+BGP15 group, showing more
proper ejection in systole, and Tei-index—indicative of global myocardial performance—was also
significantly improved in BGP-15-treated animals compared to untreated GotoK.
One possible explanation for echocardiographic findings is the hypothesis that BGP-15 treatment
may enhance relaxation properties of myocytes via affecting the activity (phosphorylation) of small
regulatory proteins, that take part in controlling sarcoplasmic/endoplasmic reticulum calcium ATPase
(SERCA2a) pump function. SERCA2a pump, a significant determinant of diastolic function, is
regulated by phosphorylation of phospholamban (PLB) protein, which increases SERCA2a activity
in its phosphorylated state (pPLB) on its Ser16 or Thr17 residues [39]. Phospholamban may
be phosphorylated on its Ser16 by the cGMP-dependent Protein Kinase G (PKG, also known as
cGKI), resulting in enhanced relaxation and increased lusitropy of the myocardium [39,40]. Here,
phospho-specific antibodies were used to determine the phosphorylation state of PLB, and analyzes
showed marked differences among treatment groups, as pPLB to PLB ratios were diminished in
the diseased GotoK animals compared to healthy controls. On the contrary, increased pPLB to PLB
ratios were found in the subjects of BGP-15-treated group. This finding suggests that the activity
of the SERCA pump increased in the GotoK+BGP-15 group, which may contribute to enhanced
relaxation of the myocytes, thus restoring diastolic parameters of the heart, confirmed by Doppler
echocardiography. A limitation of this current report is that myocyte force/contraction measurements
or calcium-sensitivity assays, which would further strengthen our findings, were not carried out.
Recent evidence suggests the crucial role of PKG in myocyte calcium homeostasis through
SERCA pump regulation. In an elegant experiment Frantz et al. showed that mice with
cardiomyocyte-restricted PKG deletion exhibited reduced phosphorylation of PLB on Ser16 and
diminished SERCA activity, resulting in deteriorated cardiac function, additionally, it was also shown
that PLB Ser16 is the specific target for PKG [41,42]. Based on these data, we attempted to detect
PKG activity in our experimental setting, by examining phosphorylation of VASP protein, using
the phospho(Ser239)-specific 16C2 antibody. Ser239 residue of VASP is a unique phosphorylation
target of PKG, thus measuring VASP phosphorylation a widely accepted method to indirectly assess
the activity of cGMP-dependent Protein Kinase G [43]. Here, we showed that along with increased
phosphorylation of phospholamban in the BGP-15-treated group, the pVASP to VASP ratios were also
elevated, suggesting increased activity of the PKG enzyme, which may explain the phosphorylation
of both downstream targets (PLB and VASP), manifested in improved diastolic parameters of the
heart. What concerns myocardial cGMP, is a limitation of this report that we did not directly measure
cGMP levels, instead, we attempted to examine the expression of the cGMP-degrading enzyme PDE9A.
Recent evidence suggests the role of PDE9A in regulation of natriuretic-peptide-derived cGMP levels
and thus activity of PKG, further, upregulation of PDE9A was previously shown in cardiac dysfunction
(traverse aortic constriction and atherosclerotic disease) models by others and our research team
as well [44,45]. Based on the aforementioned data, we determined PDE9A levels in myocardial
samples of animals, however, we failed to show significant differences between the treatment groups
in this experimental setting. As crosstalk between PDEs, and enhancement of the cGMP-system in
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cardiovascular disorders are of intense interest, several questions raised here will presumably be
addressed in further studies.
Regarding study limitations and potential bias, it needs to be addressed, that we were not able
to undoubtedly confirm the insulin-sensitizing effect of BGP-15. Although blood glucose levels
and HOMA-IR of BGP-15-treated rats were lower in comparison to GotoK, the difference was not
significant, possibly due to the relatively small sample size, or the strength of the statistical probe. From
our presented results, it may be assumed, that BGP-15 enhances PLB/SERCA pathway through the
Protein Kinase G system. To reveal the mechanism of action of BGP-15, these experiments needed to be
completed using other techniques. In addition, investigating the effects of BGP-15 on healthy animals
would further strengthen our results and support the precise characterization of the drug candidate.
In conclusion, in this report our aim was to examine the cardiovascular complications solely
caused by T2DM and to evaluate the ability of the drug candidate BGP-15 in restoring diastolic
heart functions, by comparing the agent with classical antidiabetics with proven pleiotropic effects.
BGP-15 restored the diastolic dysfunction observed in untreated animals, elevated the phosphorylation
level of VASP and phospholamban proteins, without a significant effect on vascular function or
serum glucose in this experimental setting. Since two-third of diabetes-related mortality is caused
by cardiovascular events, and BGP-15 is protective in DCM, therefore, we assume that it would be
promising to examine the combined effects of BGP-15 and classical antidiabetics in reducing disease
complications. Nevertheless, further investigations are needed to identify cellular targets and the
clinical value of the drug candidate in diabetic cardiomyopathy.
4. Materials and Methods
4.1. Animal Model and Study Design
The present study was approved by the local Ethics Committee of University of Debrecen and the
animals received humane care in accordance with the “Principles of Laboratory Animal Care” by EU
Directive 2010/63/EU (permission: 25/2013DEMÁB; 29 January 2014). 12 week-old Goto-Kakizaki
(GotoK) and Wistar (wild-type) rats were used in this present study, and rats were housed in a
controlled temperature room with a 12:12 dark:light cycle.
Rats were randomly divided into five subgroups (n = 6/group): Wistar group (served as control
group, vehicle-treated); diseased GotoK group (GotoK rats, vehicle-treated); GotoK + BGP15 group
(GotoK rats treated daily with 10 mg/kg BGP-15, per os); GotoK+MET group (GotoK rats receiving
100 mg/kg metformin daily, per os) and GotoK + PIO group (GotoK rats treated daily with 10 mg/kg
pioglitazone, per os), for 12 weeks (Figure 5). All animals were executed under deep thiopental
anesthesia (50 mg/kg, i.p.), then hearts were excised rapidly, and frozen in liquid N2, while aortic
samples were subjected to ex vivo functional experiments.
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Figure 5. Flow-chart of study design. After acclimatization, healthy control (Wistar) and diabetic
GotoK rats were randomly divided into subgroups, as follows: (I) Wistar control, treated with vehicle;
(II) diseased GotoK treated with vehicle (GotoK), (III) GotoK treated with 10 mg/kg BGP-15 (GotoK +
BGP15), (IV) GotoK trated with 100 mg/kg metformin (GotoK + MET), and (V) GotoK treated with
10 mg/kg pioglitazone (GotoK + PIO), for 12 weeks. At the endpoint, echocardiography was carried
out, serum parameters were measured, and after thoracotomy, aortic rings were cut off for ex vivo
experiments, and left ventricle myocardium was frozen for further analyses (Western blot).
4.2. Chemicals
Chemicals, buffers, primary and secondary antibodies, and ingredients of Krebs solution were
obtained either from Sigma-Aldrich-Merck KGaA (Darmstadt, Germany), and Abcam Plc. (Cambridge,
UK). Norepinephrine hydrochloride (NE; as Arterenol®), acetylcholine chloride (Ach), adenosine
5′-triphosphate disodium salt hydrate (ATP), metformin hydrochloride and pioglitazone hydrochloride
were purchased from Sigma-Aldrich-Merck KGaA. BGP-15 (Figure 6) was obtained from N-Gene
Research Laboratories (Budapest, Hungary).
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Figure 6. Chemical structure of O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime, known as
BGP-15, a hydroxamic-acid derivative small molecule (the figure was made using ChemDraw Ultra
software ver.12., CambridgeSoft, Perkin Elmer, Waltham, MA, USA).
4.3. Metabolic Profiles
Body weight of animals were measured weekly, fasting blood glucose and plasma insulin
levels were determined at the endpoint of the experiment. Blood was collected from tail vein, and
glucose levels were determined using an Accu-Chek Active blood glucose meter (Roche Diagnostics,
Mannheim, Germany). After, blood samples were centrifuged (Centrifuge 5415R; Eppendorf AG,
Hamburg, Germany) for 2 min at 4 ◦C and 10.000 rpm; then plasma was aliquoted, frozen, and stored
at −80 ◦C for subsequent determinations of basal plasma insulin level. Plasma insulin levels were
determined using a commercially available radioimmunoassay kit (RK-400CT, Institute of Isotopes of
the Hungarian Academy of Sciences, Budapest, Hungary) [46]. The homeostasis model assessment
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of insulin resistance (HOMA-IR) was calculated as follows: Fasting insulin (µIU/ml) × fasting
glucose (mmol/mL)/22.5; and β-cell function (HOMA-B) was calculated using the following formula:
20 × fasting insulin (µIU/mL)/fasting glucose (mmol/mL) − 3.5 [47].
4.4. Echocardiography
Echocardiography was carried out by a Vivid E9 sonograph with an i13L linear-array probe
(GE Healthcare, New York, NY, USA). Rats were anaesthetized with ketamine/xylazine combination
(75/5 mg/kg, respectively), chest hair was shaved and animals were positioned in a dorsal position.
Data acquisition was performed in 2D-, M-, and Doppler modes, from parasternal long- and short
axis, as well as apical 4 chamber views (Figure 7). Cardiac function was assessed in accordance with
the guideline of American Society of Echocardiography. Wall thicknesses, and chamber diameters
were measured in M-mode loops, at mid-level of the papillary muscles, from both parasternal long
axis and short axis views. Left ventricle internal diameter in diastole (LVIDd) and in systole (LVIDs),
as well as wall thicknesses were measured by standard methods. Ejection fraction was calculated
as EDV-ESV/ESV end-diastolic volume (EDV, Teiholz-formula). Diastolic function was assessed
by Doppler and Tissue Doppler imaging from apical 3- and 4 chamber views. Mitral valve closure
to opening time (MCOT), isovolumic contraction time (IVCT), ejection time (ET) and isovolumic
relaxation time (IVRT) were determined from tissue Doppler (TDI) frames. Myocardial performance
index was calculated as Tei-index (IVRT+IVCT/LVET). Data analysis was carried out using EchoPAC
PC software ver. 112, (GE Healthcare, New York, NY, USA), by a blinded reader. Three cardiac cycles
were averaged for each parameter, and data is presented as mean ±SEM.Molecules 2018, 23, x FOR PEER REVIEW  14 of 18 
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Figure 7. Representative i ages of echocardiographic experi ents. (a) Left-ventricle outflo tract
(LVOT), visualized by Doppler echocardiography; (b) parasternal long axis, - ode i age of left
ventricle; (c) 3-chamber view, mitral annular velocities, tissue Doppler mode; (d) mitral inflow velocities,
visualized by Doppler echocardiography.
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4.5. Functional Vascular Assay
After sacrificing the rats, the proximal part of the abdominal aorta was isolated, and 2 mm wide
rings were cut off (two rings from each animal). The rings were mounted horizontally at 10 mN resting
tension, using wire instruments, in 10-mL vertical organ chambers (Experimetria TSZ-04, Experimetria
Ltd, Budapest, Hungary). The chambers contained Krebs solution oxygenated with 95% O2 and 5%
CO2 (36 ◦C; pH = 7.4). The isometric contractile force of the circulatory muscle layer of aortic rings
was measured by a transducer (Experimetria SD-01,Experimetria Ltd, Budapest Hungary) and strain
gauge (Experimetria SG-01D), and recorded by a polygraph (Medicor R-61 6CH Recorder, Medicor,
Hungary).
After a 60-min incubation period, 10 nmol/L norepinephrine was administered to the rings
(a norepinephrine concentration near to the half maximal effective concentration (EC50) for Wistar
rat aorta; [48]). After the stabilization of the contractile force (pre-contraction), a cumulative Ach E/c
curve was constructed (from 10 nmol/L to 10 µmol/L).
Responses of aortic rings obtained from the same rat were averaged. The effect of Ach was defined
as a percentage decrease in the pre-contraction produced by norepinephrine (in addition to the resting
tension).
Normality of data sets was verified with Shapiro-Wilk test. Data sets (more than two)
were compared using one-way ANOVA (with Geisser–Greenhouse correction) followed by Tukey
post-testing. Difference of means was considered significant at p < 0.05. Statistical analysis was carried
out with GraphPad Prism 7.04 (GraphPad Software Inc., La Jolla, CA, USA).
4.6. Western blot
Proteins from left ventricular (LV) myocardial tissues were identified by western blot analysis. For
protein extraction, 300 mg from the deep-frozen samples (at−80 ◦C) were placed in liquid nitrogen and
grounded gently into a fine powder. The powdered tissues were homogenized in 800 µL Buffer (25 mM
Tris-HCl, pH = 8, 25 mM NaCl, 4 mM Na-orthovanadate, 10 mM NaF, 10 mM Na-pyrophosphate, 10 nM
okadaic acid, 0.5 mM EDTA, 1 mM PMSF and protease inhibitor cocktail (Sigma-Aldrich, St. Louis,
MO, USA)) by a Polytron-homogenizer (IKA-WERKE, Staufen, Germany), and samples were then
centrifuged at 10.000 g for 20 min. Total Protein concentration of the supernatant was determined using
a Bicinchoninic Acid Protein Assay Kit (QuantiPro™ BCA Assay Kit, Sigma-Aldrich-Merck KGaA,
Darmstadt, Germany). Samples containing 20 µg total protein were separated using 10, 12 or 18%
SDS-PAGE, according to the molecular size of the examined protein. After gel electrophoresis at 40 mA
for 100–120 min, proteins were transferred onto a nitrocellulose membrane (GE Heathcare, New York,
NY, USA) via electro-blotting at 25 V for 90 min. The membranes were incubated in TBS-T containing
3% BSA for 1 hour at room temperature, then were probed overnight at 4 ◦C with the following
primary antibodies: anti-phospholamban (PLB), anti-phospho(Ser16)-phospholamban (pPLB),
anti-sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a), anti-vasodilator-stimulated
phosphoprotein (VASP), anti-phopsho(Ser239)-vasodilator-stimulated phosphoprotein clone 16C2
(pVASP), anti-phosphodiesterase 9A (PDE9A) and anti-glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH), obtained from Sigma-Aldrich (Sigma-Aldrich-Merck KGaA and Abcam (Abcam Plc.,
Cambridge, UK). All primary antibodies were used as recommended by the manufacturer. After,
membranes were incubated with secondary antibodies labeled with horseradish peroxidase. Proteins
were developed with enhanced chemiluminescense reagent (WesternBright™, ECL, Advansta Inc.,
Menlo Park, CA, USA) and the detection was accomplished by a C-Digit® blot scanner with Image
Studio Digits ver. 5.2. software (LI-COR Inc., Lincoln, NE, USA) [45]. Data was averaged from
3 independent experiment (n = 6/group), and statistical analysis was carried out using Kruskal-Wallis
test with Dunn’s post-test.
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4.7. Statistical Procedures
Statistical analyses were performed by GraphPad Prism software for Windows, version 7.01
(La Jolla, CA, USA). All data are presented as the average outcome in a group (mean) ± standard error
of the mean (SEM). The D’Agostino-Pearson normality test was used to estimate Gaussian distribution.
Kruskal-Wallis test with Dunn’s post-test was used to estimate differences between groups with
non-Gaussian distribution. Probability values (p) less than 0.05 were considered significantly different.
5. Conclusions
Diabetic cardiomyopathy is an emerging problem worldwide as the incidence of type 2 diabetes
is increasing. Here, we evaluated the effectiveness of BGP-15 in alleviating cardiac dysfunction in
the Goto-Kakizaki rat model of diabetic cardiomyopathy, and compared the agent with classical
antidiabetics with proven pleiotropic effects. BGP-15-treatment restored the diastolic dysfunction
observed in untreated animals, increased the phosphorylation level of the SERCA-regulator
phospholamban and the Protein Kinase G target VASP protein, without significant effects on vascular
function or glucose homeostasis. We assume that BGP-15 improves diastolic function partly by
enhancing the activity of the phospholamban/SERCA pathway.
Author Contributions: Conceptualization, D.P., B.V., A.T., Z.P., Z.S. and B.J.; Data curation, M.B. and A.T.; Formal
analysis, A.T.; Investigation, M.B., D.P., R.G., N.H., J.N. and B.J.; Methodology, M.B., D.P., R.G., R.K., N.H., B.V.
and J.N.; Project administration, R.K., B.V. and Z.S.; Resources, R.K., A.T. and Z.S.; Supervision, Z.P. and B.J.;
Validation, Z.P., Z.S. and B.J.; Visualization, R.G.; Writing—Original draft, M.B., D.P. and B.J.
Funding: This research was funded by the European Union and the European Regional Development Fund, grant
number: GINOP-2.3.4-15-2016-00002. The APC was funded by the University of Debrecen.
Acknowledgments: The publication was supported by the GINOP-2.3.4-15-2016-00002 project (Mariann Bombicz,
Daniel Priksz, Rudolf Gesztelyi, Rita Kiss, Balazs Varga, Jozsef Nemeth, Zoltan Szilvassy, Bela Juhasz, University
of Debrecen, Department of Pharmacology and Pharmacotherapy). The project is co-financed by the European
Union and the European Regional Development Fund. The research was financed by the Higher Education
Institutional Excellence Programme of the Ministry of Human Capacities in Hungary, within the framework of
the Research and Development on Therapeutic purposes thematic programme of the University of Debrecen
(20428-3/2018/FEKUTSTRAT). The authors are sincerely grateful to Emoke Takacsne Toth (Debrecen, Hungary)
for her hard work in English editing.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Bugger, H.; Abel, E.D. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014, 57, 660–671.
[CrossRef]
2. De Ferranti, S.D.; de Boer, I.H.; Fonseca, V.; Fox, C.S.; Golden, S.H.; Lavie, C.J.; Magge, S.N.; Marx, N.;
McGuire, D.K.; Orchard, T.J.; et al. Type 1 diabetes mellitus and cardiovascular disease: A scientific statement
from the American Heart Association and American Diabetes Association. Circulation 2014, 130, 1110–1130.
[CrossRef]
3. Tate, M.; Grieve, D.J.; Ritchie, R.H. Are targeted therapies for diabetic cardiomyopathy on the horizon?
Clin. Sci. 2017, 131, 897–915. [CrossRef]
4. Jia, G.; DeMarco, V.G.; Sowers, J.R. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy.
Nat. rev. Endocrinol. 2016, 12, 144–153. [CrossRef] [PubMed]
5. Gkogkolou, P.; Bohm, M. Advanced glycation end products: Key players in skin aging?
Dermato-Endocrinology 2012, 4, 259–270. [CrossRef]
6. Bidasee, K.R.; Zhang, Y.; Shao, C.H.; Wang, M.; Patel, K.P.; Dincer, U.D.; Besch, H.R. Diabetes increases
formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase. Diabetes 2004,
53, 463–473. [CrossRef]
7. King, A.J. The use of animal models in diabetes research. Brit. J. Pharmacol. 2012, 166, 877–894.
Molecules 2019, 24, 586 16 of 18
8. D’Souza, A.; Howarth, F.C.; Yanni, J.; Dobryznski, H.; Boyett, M.R.; Adeghate, E.; Bidasee, K.R.; Singh, J.
Left ventricle structural remodelling in the prediabetic Goto-Kakizaki rat. Expe. Physiol. 2011, 96, 875–888.
[CrossRef] [PubMed]
9. El-Omar, M.M.; Yang, Z.K.; Phillips, A.O.; Shah, A.M. Cardiac dysfunction in the Goto-Kakizaki rat. A model
of type II diabetes mellitus. Basic Res. Cardiol. 2004, 99, 133–141. [CrossRef] [PubMed]
10. Alonso, N.; Moliner, P.; Mauricio, D. Pathogenesis, Clinical Features and Treatment of Diabetic
Cardiomyopathy. Adv. Exp. Med. Biol. 2018, 1067, 197–217.
11. Sena, C.M.; Matafome, P.; Louro, T.; Nunes, E.; Fernandes, R.; Seica, R.M. Metformin restores endothelial
function in aorta of diabetic rats. Brit. J. pharmacol. 2011, 163, 424–437. [CrossRef]
12. Libby, P. Metformin and vascular protection: A cardiologist’s view. Diabetes Metab. 2003, 29, S117–S120.
[CrossRef]
13. Saremi, A.; Schwenke, D.C.; Buchanan, T.A.; Hodis, H.N.; Mack, W.J.; Banerji, M.; Bray, G.A.; Clement, S.C.;
Henry, R.R.; Kitabchi, A.E.; et al. Pioglitazone slows progression of atherosclerosis in prediabetes
independent of changes in cardiovascular risk factors. Arterioscl. Throm. Vas. 2013, 33, 393–399. [CrossRef]
[PubMed]
14. Kaplan, J.; Nowell, M.; Chima, R.; Zingarelli, B. Pioglitazone reduces inflammation through inhibition of
NF-kappaB in polymicrobial sepsis. Innate immune. 2014, 20, 519–528. [CrossRef] [PubMed]
15. Gehrig, S.M.; van der Poel, C.; Sayer, T.A.; Schertzer, J.D.; Henstridge, D.C.; Church, J.E.; Lamon, S.;
Russell, A.P.; Davies, K.E.; Febbraio, M.A.; et al. Hsp72 preserves muscle function and slows progression of
severe muscular dystrophy. Nature 2012, 484, 394–398. [CrossRef]
16. Sapra, G.; Tham, Y.K.; Cemerlang, N.; Matsumoto, A.; Kiriazis, H.; Bernardo, B.C.; Henstridge, D.C.; Ooi, J.Y.;
Pretorius, L.; Boey, E.J.; et al. The small-molecule BGP-15 protects against heart failure and atrial fibrillation
in mice. Nat. commun. 2014, 5, 5705. [CrossRef] [PubMed]
17. Nascimento, T.L.; Silva, M.T.; Miyabara, E.H. BGP-15 improves contractile function of regenerating soleus
muscle. J. Muscle Res. Cell M. 2018, 39, 25–34. [CrossRef] [PubMed]
18. Literati-Nagy, B.; Tory, K.; Peitl, B.; Bajza, A.; Koranyi, L.; Literati-Nagy, Z.; Hooper, P.L.; Vigh, L.; Szilvassy, Z.
Improvement of insulin sensitivity by a novel drug candidate, BGP-15, in different animal studies. Metabo.
Syndr. Relat. D. 2014, 12, 125–131. [CrossRef]
19. Salah, H.; Li, M.; Cacciani, N.; Gastaldello, S.; Ogilvie, H.; Akkad, H.; Namuduri, A.V.; Morbidoni, V.;
Artemenko, K.A.; Balogh, G.; et al. The chaperone co-inducer BGP-15 alleviates ventilation-induced
diaphragm dysfunction. Sci. Transl. Med. 2016, 8, 350ra103. [CrossRef]
20. Pappachan, J.M.; Varughese, G.I.; Sriraman, R.; Arunagirinathan, G. Diabetic cardiomyopathy:
Pathophysiology, diagnostic evaluation and management. World J. diabetes 2013, 4, 177–189. [CrossRef]
21. Kannel, W.B.; McGee, D.L. Diabetes and cardiovascular disease. The Framingham study. Jama 1979, 241,
2035–2038. [CrossRef]
22. Radovits, T.; Korkmaz, S.; Matyas, C.; Olah, A.; Nemeth, B.T.; Pali, S.; Hirschberg, K.; Zubarevich, A.;
Gwanmesia, P.N.; Li, S.; et al. An altered pattern of myocardial histopathological and molecular changes
underlies the different characteristics of type-1 and type-2 diabetic cardiac dysfunction. J. Diabetes Res. 2015,
2015, 728741. [CrossRef] [PubMed]
23. Kuwabara, W.M.T.; Panveloski-Costa, A.C.; Yokota, C.N.F.; Pereira, J.N.B.; Filho, J.M.; Torres, R.P.;
Hirabara, S.M.; Curi, R.; Alba-Loureiro, T.C. Comparison of Goto-Kakizaki rats and high fat diet-induced
obese rats: Are they reliable models to study Type 2 Diabetes mellitus? PLoS ONE 2017, 12, e0189622.
[CrossRef] [PubMed]
24. Sourij, H.; Zweiker, R.; Wascher, T.C. Effects of pioglitazone on endothelial function, insulin sensitivity, and
glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes care 2006, 29,
1039–1045. [CrossRef] [PubMed]
25. Hadi, H.A.; Suwaidi, J.A. Endothelial dysfunction in diabetes mellitus. Vascular health risk manage. 2007, 3,
853–876.
26. Wen, Y.; Skidmore, J.C.; Porter-Turner, M.M.; Rea, C.A.; Khokher, M.A.; Singh, B.M. Relationship of glycation,
antioxidant status and oxidative stress to vascular endothelial damage in diabetes. Diabetes Obes. Metab.
2002, 4, 305–308. [CrossRef] [PubMed]
Molecules 2019, 24, 586 17 of 18
27. Akash, M.S.; Rehman, K.; Chen, S. Goto-Kakizaki rats: Its suitability as non-obese diabetic animal model for
spontaneous type 2 diabetes mellitus. Curr. Diabetes Rev. 2013, 9, 387–396. [CrossRef] [PubMed]
28. Derosa, G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: Comparison
with other oral antihyperglycaemic agents. Drugs 2010, 70, 1945–1961. [CrossRef]
29. Hallakou, S.; Doare, L.; Foufelle, F.; Kergoat, M.; Guerre-Millo, M.; Berthault, M.F.; Dugail, I.; Morin, J.;
Auwerx, J.; Ferre, P. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat.
Diabetes 1997, 46, 1393–1399. [CrossRef]
30. Fontaine, K.R.; Redden, D.T.; Wang, C.; Westfall, A.O.; Allison, D.B. Years of life lost due to obesity. JAMA
2003, 289, 187–193. [CrossRef]
31. Chawla, S.; Kaushik, N.; Singh, N.P.; Ghosh, R.K.; Saxena, A. Effect of addition of either sitagliptin or
pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled
trial. J. Pharmacol. Pharmacot. 2013, 4, 27–32.
32. Liao, H.W.; Saver, J.L.; Wu, Y.L.; Chen, T.H.; Lee, M.; Ovbiagele, B. Pioglitazone and cardiovascular outcomes
in patients with insulin resistance, pre-diabetes and type 2 diabetes: A systematic review and meta-analysis.
BMJ Open 2017, 7, e013927. [CrossRef]
33. Nagueh, S.F.; Smiseth, O.A.; Appleton, C.P.; Byrd, B.F.; Dokainish, H.; Edvardsen, T.; Flachskampf, F.A.;
Gillebert, T.C.; Klein, A.L.; Lancellotti, P.; et al. Recommendations for the Evaluation of Left Ventricular
Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and
the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiog. 2016, 29, 277–314. [CrossRef]
34. Oh, T.J.; Shin, J.Y.; Kang, G.H.; Park, K.S.; Cho, Y.M. Effect of the combination of metformin and fenofibrate
on glucose homeostasis in diabetic Goto-Kakizaki rats. Exp. Mol. Med. 2013, 45, e30. [CrossRef] [PubMed]
35. Portha, B.; Lacraz, G.; Kergoat, M.; Homo-Delarche, F.; Giroix, M.H.; Bailbe, D.; Gangnerau, M.N.; Dolz, M.;
Tourrel-Cuzin, C.; Movassat, J. The GK rat beta-cell: A prototype for the diseased human beta-cell in type 2
diabetes? Mol. Cell. Endocrinol. 2009, 297, 73–85. [CrossRef] [PubMed]
36. Yoshida, T.; Okuno, A.; Tanaka, J.; Takahashi, K.; Nakashima, R.; Kanda, S.; Ogawa, J.; Hagisawa, Y.;
Fujiwara, T. Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by
activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats. Eur. J. Pharmacol. 2009, 623,
141–147. [CrossRef] [PubMed]
37. Miki, T.; Yuda, S.; Kouzu, H.; Miura, T. Diabetic cardiomyopathy: Pathophysiology and clinical features.
Heart Fail. Rev. 2013, 18, 149–166. [CrossRef]
38. Park, J.H.; Marwick, T.H. Use and Limitations of E/e’ to Assess Left Ventricular Filling Pressure by
Echocardiography. J. Card. 2011, 19, 169–173. [CrossRef]
39. Colyer, J. Phosphorylation states of phospholamban. Ann. N.Y. Acad. Sci. 1998, 853, 79–91. [CrossRef]
40. Ramirez-Correa, G.A.; Murphy, A.M. Is phospholamban or troponin I the "prima donna" in beta-adrenergic
induced lusitropy? Circ. Res. 2007, 101, 326–327. [CrossRef]
41. Frantz, S.; Klaiber, M.; Baba, H.A.; Oberwinkler, H.; Volker, K.; Gabetaner, B.; Bayer, B.; Abebetaer, M.;
Schuh, K.; Feil, R.; et al. Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted
inactivation of cyclic GMP-dependent protein kinase I. Eur. Heart J. 2013, 34, 1233–1244. [CrossRef] [PubMed]
42. Gorbe, A.; Giricz, Z.; Szunyog, A.; Csont, T.; Burley, D.S.; Baxter, G.F.; Ferdinandy, P. Role of cGMP-PKG
signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation.
Basic Rese. Cardiol. 2010, 105, 643–650. [CrossRef]
43. Smolenski, A.; Bachmann, C.; Reinhard, K.; Honig-Liedl, P.; Jarchau, T.; Hoschuetzky, H.; Walter, U. Analysis
and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact
cells using a phosphospecific monoclonal antibody. J. Biol. Chem. 1998, 273, 20029–20035. [CrossRef]
44. Lee, D.I.; Zhu, G.; Sasaki, T.; Cho, G.S.; Hamdani, N.; Holewinski, R.; Jo, S.H.; Danner, T.; Zhang, M.;
Rainer, P.P. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Nature 2015, 519, 472–476. [CrossRef] [PubMed]
45. Priksz, D.; Bombicz, M.; Varga, B.; Kurucz, A.; Gesztelyi, R.; Balla, J.; Toth, A.; Papp, Z.; Szilvassy, Z.;
Juhasz, B. Upregulation of Myocardial and Vascular Phosphodiesterase 9A in A Model of Atherosclerotic
Cardiovascular Disease. Int. J. Mol. Sci. 2018, 19, 2882. [CrossRef]
Molecules 2019, 24, 586 18 of 18
46. Kovacs, D.; Simon, Z.; Hari, P.; Malnasi-Csizmadia, A.; Hegedus, C.; Drimba, L.; Nemeth, J.; Sari, R.;
Szilvassy, Z.; Peitl, B. Identification of PPARgamma ligands with One-dimensional Drug Profile Matching.
Drug Des, Dev. Ther. 2013, 7, 917–928.
47. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model
assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations
in man. Diabetologia 1985, 28, 412–419. [CrossRef]
48. Szabo, K.; Gesztelyi, R.; Lampe, N.; Kiss, R.; Remenyik, J.; Pesti-Asboth, G.; Priksz, D.; Szilvassy, Z.; Juhasz, B.
Fenugreek (Trigonella Foenum-Graecum) Seed Flour and Diosgenin Preserve Endothelium-Dependent
Arterial Relaxation in a Rat Model of Early-Stage Metabolic Syndrome. Int. J. Mol. Sci. 2018, 19, 798.
[CrossRef]
Sample Availability: Samples of the compounds are not available from the authors.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
